An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the aromatase inhibitors letrozole and anastrozole
- 30 November 2003
- journal article
- clinical trial
- Published by Elsevier BV in European Journal of Cancer
- Vol. 39 (16), 2318-2327
- https://doi.org/10.1016/s0959-8049(03)00630-0
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Endocrine and clinical endpoints of exemestane as neoadjuvant therapy.Cancer Control, 2002
- Influence of Letrozole and Anastrozole on Total Body Aromatization and Plasma Estrogen Levels in Postmenopausal Breast Cancer Patients Evaluated in a Randomized, Cross-Over StudyJournal of Clinical Oncology, 2002
- Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer.Endocrine-Related Cancer, 2001
- Phase III, Multicenter, Double-Blind, Randomized Study of Letrozole, an Aromatase Inhibitor, for Advanced Breast Cancer Versus Megestrol AcetateJournal of Clinical Oncology, 2001
- Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitorsThe Journal of Steroid Biochemistry and Molecular Biology, 2001
- Aromatase Inhibitors in the Treatment and Prevention of Breast CancerJournal of Clinical Oncology, 2001
- Exemestane Is Superior to Megestrol Acetate After Tamoxifen Failure in Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Randomized Double-Blind TrialJournal of Clinical Oncology, 2000
- Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancerAnnals of Oncology, 1998
- Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.Journal of Clinical Oncology, 1998
- A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancerEuropean Journal Of Cancer, 1996